Sold Out

Palladia (toceranib phosphate) 50mg, 30 tablets

$1,046.26

Shipping calculated at checkout

Prescription Required

Zoetis SKU: 10003325

Free Ground Shipping on Prescription Pharmacy orders above $49

Oral Mast Cell Tumor Treatment for Dogs

Product Description

PALLADIA® Tablets are an FDA-sanctioned oral therapy for dogs suffering from recurring Patnaik grade II or III cutaneous mast cell tumors. This specific tyrosine kinase inhibitor functions by obstructing the growth of tumor cells and diminishing their blood supply. Intended for use under veterinary prescription, it provides a clinically validated systemic treatment solution when surgery on its own does not suffice.

Benefits

  • Targeted Therapy: Specifically inhibits receptor tyrosine kinases, including KIT, VEGFR2, and PDGFR, involved in tumor growth.
  • Controls Tumor Growth: Helps reduce tumor cell proliferation and limits the formation of blood vessels supplying tumors.
  • Oral Administration: Administered by mouth every other day, allowing convenient at-home dosing under veterinary guidance.
  • FDA Approved: Approved by the U.S. Food and Drug Administration for use in eligible dogs.

Variants

10 mg tablets
15 mg tablets
50 mg tablets

Ingredients

Active Ingredients

Toceranib phosphate

How to Use

Recommended-Dosage Chart

Dog Body Weight (lb)

Dog Body Weight (kg)

Total Dose (mg)

10 mg Tablets

15 mg Tablets

50 mg Tablets

11.0 to 11.8

5.0 to 5.3

15 mg

-

1

-

15.3 to 18.5

7.0 to 8.4

25 mg

1

1

-

22.1 to 25.4

10.1 to 11.5

35 mg

2

1

-

28.8 to 32.2

13.1 to 14.6

45 mg

-

3

-

32.3 to 35.5

14.7 to 16.1

50 mg

-

-

1

45.7 to 50.7

20.8 to 23.0

70 mg

-

2

1

66.0 to 71.2

30.0 to 32.3

100 mg

-

-

2

94.9 to 105.0

43.1 to 47.6

150 mg

-

-

3

128.9 to 138.9

58.5 to 63.0

200 mg

-

-

4

191.7 to 220.5

87.0 to 100.0

300 mg

-

-

6

The initial recommended dosage is 3.25 mg per kg body weight administered orally every other day.

Dosage & Administration Instructions

  • Every Alternate Day: Administer orally starting at a dose of 3.25 mg per kg every other day.
  • Veterinary Oversight: Adjustments to the dose or a temporary halt in administration may be necessary due to side effects.
  • Prescription Required: This medication needs to be prescribed and monitored by a qualified veterinarian.

Disclaimer: This dosage information is provided by the manufacturer. Always consult your veterinarian before administering or adjusting any supplement for your pet.

Additional Information

Precautions

  • Breeding Limitation: Avoid using in breeding dogs or in females that are pregnant or nursing.
  • Bloodwork Monitoring: It is advised to conduct regular lab tests because of possible blood-related issues.
  • Gastrointestinal Caution: Exercise care with dogs that have a history of gastrointestinal bleeding or ulcers.

Possible Side Effects

  • Digestive Upset: Diarrhea, vomiting, and decreased appetite were commonly reported during clinical studies.
  • Lethargy Signs: Dogs may experience reduced activity levels or generalized weakness.
  • Lameness Issues: Lameness has been observed in treated dogs during clinical evaluation.
  • Blood Abnormalities: Neutropenia and hypoalbuminemia were documented in treated patients.

Storage Information

  • Room Temperature: Store at controlled room temperature as indicated on the product labeling.
  • Secure Location: Keep out of reach of children and other animals.

Shipping & Return

We offer ground, express, priority, and international delivery; see our shipping policy for details.

For return instructions or product concerns, please refer to our detailed refund policy.

Prescription items are NON-RETURNABLE and NON-REFUNDABLE.

Frequently Asked Questions

Q1: What condition does PALLADIA treat in dogs?

Ans: PALLADIA is approved for the treatment of Patnaik grade II or III recurrent cutaneous mast cell tumors in dogs, with or without involvement of regional lymph nodes. It is indicated only for eligible canine patients under veterinary supervision.

Q2: How does PALLADIA work?

Ans: PALLADIA functions as a receptor tyrosine kinase inhibitor. It targets receptors such as KIT, VEGFR2, and PDGFR that contribute to tumor growth and blood vessel development, thereby helping control the progression of mast cell tumors.

Q3: What is the recommended starting dose?

Ans: The recommended initial dose is 3.25 mg per kg of body weight administered orally every other day. Your veterinarian may adjust dosing or pause treatment depending on how your dog responds.

Q4: What side effects should pet owners watch for?

Ans: Frequent side effects consist of diarrhea, vomiting, reduced appetite, fatigue, difficulty walking, and weight loss. Lab findings like neutropenia and hypoalbuminemia have also been noted during clinical studies.

Q5: Is PALLADIA safe for pregnant dogs?

Ans: PALLADIA should not be administered to breeding dogs or to pregnant or lactating females. As an antiangiogenic agent, it may interfere with fetal blood vessel development and pose risks during pregnancy.